DK0866720T3 - OB-protein til forögelse af mager kropsmasse - Google Patents

OB-protein til forögelse af mager kropsmasse

Info

Publication number
DK0866720T3
DK0866720T3 DK96938773T DK96938773T DK0866720T3 DK 0866720 T3 DK0866720 T3 DK 0866720T3 DK 96938773 T DK96938773 T DK 96938773T DK 96938773 T DK96938773 T DK 96938773T DK 0866720 T3 DK0866720 T3 DK 0866720T3
Authority
DK
Denmark
Prior art keywords
protein
body mass
lean body
increasing lean
increasing
Prior art date
Application number
DK96938773T
Other languages
Danish (da)
English (en)
Inventor
Christopher Francis Toombs
Mary Ann Pelleymounter
Michael Benjamin Mann
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of DK0866720T3 publication Critical patent/DK0866720T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK96938773T 1995-11-22 1996-11-04 OB-protein til forögelse af mager kropsmasse DK0866720T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56173295A 1995-11-22 1995-11-22
PCT/US1996/017718 WO1997018833A1 (en) 1995-11-22 1996-11-04 Methods of increasing lean tissue mass using ob protein compositions

Publications (1)

Publication Number Publication Date
DK0866720T3 true DK0866720T3 (da) 2004-06-14

Family

ID=24243198

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96938773T DK0866720T3 (da) 1995-11-22 1996-11-04 OB-protein til forögelse af mager kropsmasse

Country Status (15)

Country Link
EP (3) EP0956862A1 (cg-RX-API-DMAC7.html)
JP (2) JP4173914B2 (cg-RX-API-DMAC7.html)
AT (2) ATE259243T1 (cg-RX-API-DMAC7.html)
AU (3) AU7607496A (cg-RX-API-DMAC7.html)
CA (2) CA2358862A1 (cg-RX-API-DMAC7.html)
DE (2) DE69638119D1 (cg-RX-API-DMAC7.html)
DK (1) DK0866720T3 (cg-RX-API-DMAC7.html)
ES (2) ES2339846T3 (cg-RX-API-DMAC7.html)
IL (2) IL124442A0 (cg-RX-API-DMAC7.html)
MX (1) MX9803992A (cg-RX-API-DMAC7.html)
NZ (3) NZ512083A (cg-RX-API-DMAC7.html)
PT (1) PT866720E (cg-RX-API-DMAC7.html)
SI (1) SI0866720T1 (cg-RX-API-DMAC7.html)
WO (1) WO1997018833A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA969605B (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
NZ512083A (en) * 1995-11-22 2003-02-28 Amgen Inc Methods of increasing lean tissue mass using OB protein compositions
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
JP2000505791A (ja) * 1996-01-25 2000-05-16 イーライ・リリー・アンド・カンパニー 肥満症タンパク質類似体化合物およびその製剤
EP0917469A1 (en) * 1996-04-19 1999-05-26 ZymoGenetics, Inc. Methods for inducing bone formation
RS49927B (sr) * 1996-12-20 2008-09-29 Amgen Inc., Preparati ob fuzionog proteina i postupci
CA2274799A1 (en) * 1996-12-20 1998-07-02 Eli Lilly And Company Anti-obesity proteins
US20020019352A1 (en) * 1997-04-17 2002-02-14 David N. Brems Stable, active, human ob protein compositions and methods
EP0950417A3 (en) * 1998-02-23 2000-02-23 Pfizer Products Inc. Treatment of skeletal disorders
AU3863699A (en) * 1998-04-20 1999-11-08 Mayo Foundation For Medical Education And Research Treatment of osteoporosis with leptin
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
WO2000024418A1 (en) * 1998-10-27 2000-05-04 Eli Lilly And Company Prevention of muscle mass loss with leptin receptor ligands
PT1151102E (pt) * 1999-02-12 2006-07-31 Amgen Inc Composicoes de leptina glicosilada e metodos afins
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
PT2219031E (pt) 2001-10-22 2013-05-17 Amgen Inc Uso de leptina para tratamento de lipoatrofia humana e método para determinar predisposição ao referido tratamento
WO2003077847A2 (en) 2002-03-12 2003-09-25 Merck & Co., Inc. Substituted amides
WO2006005058A2 (en) * 2004-06-30 2006-01-12 Nektar Therapeutics Al, Corporation Polymer-factor ix moiety conjugates
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
DK1814590T4 (da) 2004-11-01 2014-02-24 Amylin Pharmaceuticals Llc Behandling af obesitet og beslægtede sygdomme.
WO2008048691A2 (en) * 2006-10-18 2008-04-24 Amylin Pharmaceuticals, Inc. Use of leptin for treating post-lipectomy ectopic fat deposition and other post-lipectomy associated disorders
WO2009149379A2 (en) 2008-06-05 2009-12-10 Regents Of The University Of Michigan Use of leptin for the treatment of fatty liver diseases and conditions
BR112013007385B1 (pt) 2010-09-28 2022-07-26 Amylin Pharmaceuticals, Llc Polipeptídeo quimérico, seu uso e composição que o compreende
AU2013323528B2 (en) 2012-09-27 2016-11-10 The Children's Medical Center Corporation Compounds for the treatment of obesity and methods of use thereof
HUE042196T2 (hu) 2013-11-26 2019-06-28 Childrens Medical Ct Corp Vegyületek elhízás kezelésére és alkalmazási eljárásaik
US20170209408A1 (en) 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
DK3509624T3 (da) 2016-09-12 2023-11-13 Amryt Pharmaceuticals Inc Fremgangsmåder til detektering af anti-leptin-neutraliserende antistoffer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1228925B (it) * 1987-08-07 1991-07-10 Eniricerche Spa Procedimento per la preparazione dell'ormone della crescita umano
DK173142B1 (da) * 1988-08-24 2000-02-07 Natinco Nv Fremgangsmåde til forbedring af kødkvaliteten og foderomsætningseffektiviteten for grise
US5028440A (en) * 1990-01-30 1991-07-02 Iowa State University Research Foundation, Inc. Method of raising meat producing animals to increase lean tissue development
AU7535394A (en) * 1993-08-13 1995-03-14 Putzmeister-Werk Maschinenfabrik Gmbh Process and device for treating the surface of large objects
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
NZ512083A (en) * 1995-11-22 2003-02-28 Amgen Inc Methods of increasing lean tissue mass using OB protein compositions
CZ9802013A3 (cs) * 1995-12-27 1998-09-16 Genentech, Inc. Deriváty OB proteinu, chimerní OB polypeptidy, prostředky pro léčbu obezity a dalších fyziologických stavů a způsob léčení těmito prostředky, kódující sekvence pro OB protein, expresní vektor nesoucí tuto sekvenci, buňky transformované tímto vektorem a způsob jejich kultivace, a způsob navození růstu buněk s pomocí OB proteinu
RS49927B (sr) * 1996-12-20 2008-09-29 Amgen Inc., Preparati ob fuzionog proteina i postupci
CN1202862C (zh) * 1997-04-17 2005-05-25 安姆根有限公司 包含具有抗体Fc链的稳定、有活性人OB蛋白的结合物的组合物及方法

Also Published As

Publication number Publication date
SI0866720T1 (en) 2004-10-31
ATE455554T1 (de) 2010-02-15
EP0866720A1 (en) 1998-09-30
CA2236163A1 (en) 1997-05-29
DE69631544D1 (de) 2004-03-18
IL124442A0 (en) 1998-12-06
ES2217327T3 (es) 2004-11-01
DE69638119D1 (de) 2010-03-11
PT866720E (pt) 2004-06-30
AU763769B2 (en) 2003-07-31
IL127926A (en) 2006-08-20
MX9803992A (es) 1998-09-30
IL127926A0 (en) 1999-11-30
JP4173914B2 (ja) 2008-10-29
NZ512083A (en) 2003-02-28
EP1285664A3 (en) 2003-07-30
JP2000500492A (ja) 2000-01-18
JP4227325B2 (ja) 2009-02-18
ATE259243T1 (de) 2004-02-15
ZA969605B (en) 1997-06-02
AU4265200A (en) 2000-09-21
AU763755B2 (en) 2003-07-31
EP0866720B1 (en) 2004-02-11
EP1285664A2 (en) 2003-02-26
AU4265300A (en) 2000-09-07
JP2002206000A (ja) 2002-07-23
EP1285664B1 (en) 2010-01-20
CA2358862A1 (en) 1997-05-29
ES2339846T3 (es) 2010-05-26
EP0956862A1 (en) 1999-11-17
WO1997018833A1 (en) 1997-05-29
DE69631544T2 (de) 2004-12-23
NZ527007A (en) 2005-01-28
AU7607496A (en) 1997-06-11
NZ511617A (en) 2003-08-29

Similar Documents

Publication Publication Date Title
DK0866720T3 (da) OB-protein til forögelse af mager kropsmasse
IL148079A0 (en) Human ctla-4 antibodies and compositions containing the same
ATE295416T1 (de) Humanisiertes grünes-fluoreszenzprotein und methoden
ATE378403T1 (de) Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern
DK0713529T3 (da) Vækst-/differentieringsfaktor af TGF-beta-familien
DE69731285D1 (de) Langwellig fluorezierende proteine
DE3868910D1 (de) Implantat zur befestigung von zahnprothesen.
EA200300464A1 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ
DE3750342D1 (de) Menschliches gamma-interferon-spezifisches Rezeptorprotein, Antikörper gegen dieses Protein, Verfahren zur Herstellung dieses Proteins und dieses Antikörpers und dieses Protein und diesen Antikörper enthaltende Zusammensetzungen.
DK0845943T3 (da) Nye peptider afledt fra humant heat shock protein 60 til behandling af diabetes, sammensætninger, fremgangsmåder og kits
DE69737651D1 (de) Cortistatin: neuropeptide, zusammensetzungen und methoden
DE69735039D1 (de) Acetylhydrolase des Plättchen aktivierenden Faktors, und entsprechendes Gen
DK0972520T3 (da) Frysetörret sammensætning af humant, knoglemorfogenetisk protein MP52
SE9803962D0 (sv) Nucleic acid encoding a nervous tissue sodium channel
DK0601152T3 (da) Osteosyntesehjælpemiddel til fiksering af knogler.
DE69409961D1 (de) Triarylethylenderivate zur therapeutischen verwendung
ES2175842T3 (es) Antagonistas de kv2.1.
EP1191096A4 (en) NEW PROTEIN AND ITS DNA
EP1467207A4 (en) Screening method
AU8499501A (en) Slo2 and slo4, novel potassium channel proteins from human brain
ATE336503T1 (de) Cyclophilin als allergen identifiziert
FI956041A0 (fi) Kompositiot ja diagnostiset menetelmät, joissa käytetään monoklonaalisia vasta-aineita CD44V6 vastaan